HK1208621A1 - Combination of sglt2 inhibitor and anti-hypertension drug - Google Patents
Combination of sglt2 inhibitor and anti-hypertension drug Download PDFInfo
- Publication number
- HK1208621A1 HK1208621A1 HK15109273.2A HK15109273A HK1208621A1 HK 1208621 A1 HK1208621 A1 HK 1208621A1 HK 15109273 A HK15109273 A HK 15109273A HK 1208621 A1 HK1208621 A1 HK 1208621A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- diabetes
- disease
- medicament
- hypertension
- glucitol
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261695016P | 2012-08-30 | 2012-08-30 | |
| US61/695,016 | 2012-08-30 | ||
| PCT/JP2013/073300 WO2014034842A1 (ja) | 2012-08-30 | 2013-08-30 | Ｓｇｌｔ２阻害薬と抗高血圧薬との組み合わせ |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1208621A1 true HK1208621A1 (en) | 2016-03-11 |
Family
ID=50183647
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK15109273.2A HK1208621A1 (en) | 2012-08-30 | 2013-08-30 | Combination of sglt2 inhibitor and anti-hypertension drug |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US9320727B2 (enExample) |
| EP (1) | EP2891499A4 (enExample) |
| JP (2) | JP6198013B2 (enExample) |
| KR (1) | KR20150046125A (enExample) |
| CN (1) | CN104780942A (enExample) |
| AU (1) | AU2013309904A1 (enExample) |
| BR (1) | BR112015004012A2 (enExample) |
| CA (1) | CA2883118A1 (enExample) |
| HK (1) | HK1208621A1 (enExample) |
| IN (1) | IN2015DN01975A (enExample) |
| MX (1) | MX2015002572A (enExample) |
| PH (1) | PH12015500434B1 (enExample) |
| RU (1) | RU2015110979A (enExample) |
| SG (1) | SG11201501510SA (enExample) |
| TW (1) | TW201414472A (enExample) |
| WO (1) | WO2014034842A1 (enExample) |
| ZA (1) | ZA201502009B (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101943382B1 (ko) * | 2017-09-19 | 2019-01-29 | 오토텔릭바이오 주식회사 | Sglt-2 저해제 및 안지오텐신 수용체 차단제를 포함하는 의약 조성물 |
| CN109806397A (zh) * | 2017-11-20 | 2019-05-28 | 江苏恒瑞医药股份有限公司 | Sglt2抑制剂与arb联合在制备治疗高血压等疾病的药物中的用途 |
| KR102131359B1 (ko) * | 2018-09-07 | 2020-07-07 | 오토텔릭바이오 주식회사 | 안정성이 향상된 의약 조성물 |
| JP7659783B2 (ja) | 2019-09-13 | 2025-04-10 | 国立大学法人富山大学 | 急性心不全における体液貯留改善薬 |
| CA3180674A1 (en) * | 2020-04-22 | 2021-10-28 | Bayer Aktiengesellschaft | Combination of finerenone and a sglt2 inhibitor for the treatment and/or prevention of cardiovascular and/or renal diseases |
| US20230346817A1 (en) * | 2020-08-17 | 2023-11-02 | Beijing Creatron Institute Of Pharmaceutical Research Co. Ltd. | Composition and use of sglt-2 inhibitor and angiotensin receptor blockers |
| WO2022176981A1 (ja) * | 2021-02-19 | 2022-08-25 | 大正製薬株式会社 | 経口フィルム製剤 |
| KR102707874B1 (ko) * | 2021-10-27 | 2024-09-25 | 주식회사 메디테이크 | 안지오텐신 수용체 차단제 및 sglt2 억제제를 포함하는 복합 조성물 |
| EP4640223A1 (en) * | 2022-12-20 | 2025-10-29 | THPharm Corp. | Pharmaceutical composition for prevention or treatment of cardiovascular disease, comprising sodium-glucose cotransporter-2 inhibitor and angiotensin ii receptor blocker |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PH12000002657B1 (en) * | 1999-10-12 | 2006-02-21 | Bristol Myers Squibb Co | C-aryl glucoside SGLT2 inhibitors |
| US6515117B2 (en) * | 1999-10-12 | 2003-02-04 | Bristol-Myers Squibb Company | C-aryl glucoside SGLT2 inhibitors and method |
| DE102004048388A1 (de) | 2004-10-01 | 2006-04-06 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | D-Pyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
| TW200637839A (en) * | 2005-01-07 | 2006-11-01 | Taisho Pharmaceutical Co Ltd | 1-thio-d-glucitol derivatives |
| JP5194588B2 (ja) * | 2006-07-06 | 2013-05-08 | 大正製薬株式会社 | １−チオ−ｄ−グルシトール誘導体を有効成分として含有する糖尿病の予防又は治療剤 |
| PE20090185A1 (es) * | 2007-03-22 | 2009-02-28 | Bristol Myers Squibb Co | Formulaciones farmaceuticas que contienen un inhibidor sglt2 |
| US20080287529A1 (en) * | 2007-05-18 | 2008-11-20 | Bristol-Myers Squibb Company | Crystal structures of sglt2 inhibitors and processes for preparing same |
| WO2010048358A2 (en) * | 2008-10-22 | 2010-04-29 | Auspex Pharmaceutical, Inc. | Ethoxyphenylmethyl inhibitors of sglt2 |
| SG2014012462A (en) | 2009-04-16 | 2014-05-29 | Taisho Pharmaceutical Co Ltd | Pharmaceutical compositions |
| US8685934B2 (en) * | 2009-05-27 | 2014-04-01 | Bristol-Myers Squibb Company | Methods for treating extreme insulin resistance in patients resistant to previous treatment with other anti-diabetic drugs employing an SGLT2 inhibitor and compositions thereof |
-
2013
- 2013-08-30 US US14/424,096 patent/US9320727B2/en not_active Expired - Fee Related
- 2013-08-30 KR KR20157006606A patent/KR20150046125A/ko not_active Withdrawn
- 2013-08-30 JP JP2014533107A patent/JP6198013B2/ja active Active
- 2013-08-30 SG SG11201501510SA patent/SG11201501510SA/en unknown
- 2013-08-30 WO PCT/JP2013/073300 patent/WO2014034842A1/ja not_active Ceased
- 2013-08-30 EP EP13832429.8A patent/EP2891499A4/en not_active Withdrawn
- 2013-08-30 IN IN1975DEN2015 patent/IN2015DN01975A/en unknown
- 2013-08-30 CN CN201380045221.4A patent/CN104780942A/zh active Pending
- 2013-08-30 TW TW102131295A patent/TW201414472A/zh unknown
- 2013-08-30 HK HK15109273.2A patent/HK1208621A1/xx unknown
- 2013-08-30 RU RU2015110979A patent/RU2015110979A/ru not_active Application Discontinuation
- 2013-08-30 CA CA2883118A patent/CA2883118A1/en not_active Abandoned
- 2013-08-30 MX MX2015002572A patent/MX2015002572A/es unknown
- 2013-08-30 AU AU2013309904A patent/AU2013309904A1/en not_active Abandoned
- 2013-08-30 BR BR112015004012A patent/BR112015004012A2/pt not_active IP Right Cessation
-
2015
- 2015-02-27 PH PH12015500434A patent/PH12015500434B1/en unknown
- 2015-03-24 ZA ZA2015/02009A patent/ZA201502009B/en unknown
-
2017
- 2017-05-31 JP JP2017107661A patent/JP6358515B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP2891499A4 (en) | 2016-02-24 |
| KR20150046125A (ko) | 2015-04-29 |
| BR112015004012A2 (pt) | 2017-07-04 |
| CN104780942A (zh) | 2015-07-15 |
| JPWO2014034842A1 (ja) | 2016-08-08 |
| TW201414472A (zh) | 2014-04-16 |
| JP2017186353A (ja) | 2017-10-12 |
| US9320727B2 (en) | 2016-04-26 |
| PH12015500434A1 (en) | 2015-04-20 |
| IN2015DN01975A (enExample) | 2015-08-14 |
| MX2015002572A (es) | 2015-06-05 |
| CA2883118A1 (en) | 2014-03-06 |
| ZA201502009B (en) | 2016-07-27 |
| RU2015110979A (ru) | 2016-10-20 |
| AU2013309904A1 (en) | 2015-03-19 |
| JP6198013B2 (ja) | 2017-09-20 |
| WO2014034842A1 (ja) | 2014-03-06 |
| SG11201501510SA (en) | 2015-04-29 |
| PH12015500434B1 (en) | 2022-04-22 |
| JP6358515B2 (ja) | 2018-07-18 |
| EP2891499A1 (en) | 2015-07-08 |
| US20150320721A1 (en) | 2015-11-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6358515B2 (ja) | Ｓｇｌｔ２阻害薬と抗高血圧薬との組み合わせ | |
| EP4321157B1 (en) | New use of a combination of an angiotensin receptor blocker (arb) with a neutral endopeptidase inhibitor (nepi) | |
| JP5685192B2 (ja) | 高尿酸血症と関連病態の治療の方法 | |
| EP2419097A1 (en) | Pharmaceutical compositions | |
| US20230201174A1 (en) | Combination of finerenone and a sglt2 inhibitor for the treatment and/or prevention of cardiovascular and/or renal diseases | |
| JP2025111453A (ja) | 慢性腎臓病を有する糖尿病患者を治療するためのカナグリフロジン | |
| CA3142325A1 (en) | Compositions and methods for treating metabolic disease | |
| TW201313679A (zh) | 吲哚氫胺酸和吲哚啉氫胺酸於治療心臟衰竭或神經損傷的用途 | |
| CA3258617A1 (en) | SOLUBLE GUANYLATE CYCLASE ACTIVATORS FOR USE IN THE TREATMENT OF HEART FAILURE WITH PRESERVED EJECTION FRACTION IN WOMEN | |
| AU2002309211B2 (en) | Treatment of renal fibrosis | |
| EP2837380B1 (en) | Lercanidipine hydrochloride and losartan potassium compound preparation and preparation method thereof | |
| AU2002309211A1 (en) | Treatment of renal fibrosis | |
| EP2919780A1 (en) | 1,3-dihydroimidazole-2-thione derivatives for use in the treatment of pulmonary arterial hypertension and lung injury | |
| CN107072977B (zh) | Nep抑制剂药物组合及其应用 | |
| JP4925406B2 (ja) | 糖尿病性腎症の予防及び／又は治療剤 | |
| TW201729801A (zh) | 協同性醫藥組合物 | |
| CN120284970A (zh) | Cb-839在制备治疗糖尿病肾脏病药物中的应用 | |
| MX2015002646A (es) | Otamixaban para uso en el tratamiento de sindrome coronario agudo sin elevacion de st en pacientes programados para ser sometidos a injerto de bypass de arteria coronaria. | |
| US20090281083A1 (en) | Combination Product | |
| WO2005073218A1 (ja) | バイパス術に伴う血管攣縮治療剤 |